Advances in adjuvant therapy of biliary tract cancer: an overview of current clinical evidence based on phase II and III trials

A Belkouz; J W Wilmink; N Haj Mohammad; J Hagendoorn; J de Vos-Geelen; C H C Dejong; M Y V Homs; B Groot Koerkamp; T M van Gulik; M G H van Oijen; C J A Punt; H Klümpen

doi:10.1016/j.critrevonc.2020.102975

Advances in adjuvant therapy of biliary tract cancer: an overview of current clinical evidence based on phase II and III trials

Crit Rev Oncol Hematol. 2020 Jul:151:102975. doi: 10.1016/j.critrevonc.2020.102975. Epub 2020 Apr 27.

Authors

A Belkouz¹, J W Wilmink¹, N Haj Mohammad², J Hagendoorn³, J de Vos-Geelen⁴, C H C Dejong⁵, M Y V Homs⁶, B Groot Koerkamp⁷, T M van Gulik⁸, M G H van Oijen¹, C J A Punt¹, H Klümpen⁹

Affiliations

¹ Amsterdam UMC, Dept. of Medical Oncology, University of Amsterdam, Cancer Center Amsterdam, Amsterdam, the Netherlands.
² UMC Utrecht Cancer Center/RAKU, Dept. of Medical Oncology, Utrecht University, Utrecht, the Netherlands.
³ UMC Utrecht Cancer Center/RAKU, Dept. of Surgery, Utrecht University, Utrecht the Netherlands.
⁴ Maastricht UMC+, GROW - School for Oncology and Developmental Biology, Dept. Internal Medicine, Div. of of Medical Oncology, Maastricht, the Netherlands.
⁵ Department of Surgery and School of Nutrition and Translational Research in Metabolism, Maastricht UMC+, Maastricht, the Netherlands and Department of Surgery, Universitätsklinikum Aachen, Aachen, Germany.
⁶ Erasmus MC, Dept. of Medical Oncology, Rotterdam, the Netherlands.
⁷ Erasmus MC, Dept. of Surgery Rotterdam, the Netherlands.
⁸ Amsterdam UMC, Dept. of Surgery, University of Amsterdam, Cancer Center Amsterdam, Amsterdam, the Netherlands.
⁹ Amsterdam UMC, Dept. of Medical Oncology, University of Amsterdam, Cancer Center Amsterdam, Amsterdam, the Netherlands. Electronic address: h.klumpen@amsterdamumc.nl.

PMID: 32464483
DOI: 10.1016/j.critrevonc.2020.102975

Abstract

Patients with biliary tract cancer (BTC) have a high recurrence rate after complete surgical resection. To reduce the risk of recurrence and to improve survival, several chemotherapeutic agents that have shown to be active in locally advanced and metastatic BTC have been investigated in the adjuvant setting in prospective clinical trials. Based on the results of the BILCAP phase III trial, capecitabine was adapted as the standard of care by the ASCO clinical practice guideline. Ongoing randomized controlled trials mainly compare capecitabine with gemcitabine-based chemotherapy or chemoradiotherapy. This review provides an update of adjuvant therapy in BTC based on published data of phase II and III trials and ongoing randomized controlled trials (RCTs).

Keywords: Adjuvant therapy; Biliary tract cancer; Chemoradiotherapy; Chemotherapy; Cholangiocarcinoma; Neoadjuvant therapy.

Publication types

Review

MeSH terms

Antimetabolites, Antineoplastic / therapeutic use*
Antineoplastic Combined Chemotherapy Protocols
Biliary Tract Neoplasms / pathology
Biliary Tract Neoplasms / therapy*
Capecitabine / therapeutic use*
Chemotherapy, Adjuvant*
Clinical Trials, Phase II as Topic*
Clinical Trials, Phase III as Topic*
Humans
Neoplasm Recurrence, Local
Prospective Studies

Substances

Antimetabolites, Antineoplastic
Capecitabine